PM 19

Drug Profile

PM 19

Alternative Names: Polyoxometalase 19

Latest Information Update: 22 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Terumo
  • Class Antivirals
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections; HIV infections

Most Recent Events

  • 01 Mar 2000 A study in guinea pigs has been added to the pharmacodynamics section
  • 10 Jul 1998 A study has been added to the antimicrobial activity section
  • 01 Nov 1994 Terumo is developing PM 19 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top